DadFinStart your free week
DadFin › Stocks › Healthcare › QUIT

Achieve Life Sciences, Inc. (QUIT) stock score

Healthcare · Biotechnology · United States

$6.06 ▼ -4.11% today

22.4
Dad Score, out of 100
weak

Achieve Life Sciences, Inc. (QUIT) is a Biotechnology company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 22.4 out of 100 on the Dad Score, a weak reading that places the business ahead of 22% of the 5,684 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #686 of 956. Its weakest axes are quality, price action and liquidity.

Scores from the run of Nov 15, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Weak
Growth
Average
Price action
Below average
Risk
Average
Conviction
Average
Liquidity
Below average
Macro
Below average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)-9.2×
Dividend yield0.00%
Return on capital-164.6%
Operating margin0.0%
Revenue growth (YoY)+0.0%
FCF yield-7.7%
Net debt / EBITDA3.00×
Piotroski F-Score1 / 9
52-week change+43.6%
Market cap$652M
Next earnings—

What subscribers see on QUIT

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate75.0good$136.6B
REGNRegeneron Pharmaceuticals, Inc.98.6strong$98.8B
MRNAModerna, Inc.31.8weak$90.4B
ARGXargenx SE86.7strong$60.4B
ONCBeOne Medicines AG95.0strong$47.6B
RPRXRoyalty Pharma plc98.2strong$39.9B
RVMDRevolution Medicines, Inc.44.8middling$37.3B
GMABGenmab A/S63.2middling$31.7B

Prices from DadFin's live feed (refreshed about every 30 minutes in the session); scores from the weekly run of Nov 15, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.